Evidence-led writing on the molecules, mechanisms and formulation science behind anti-aging and longevity care — for clinicians, pharmacists and partners across the Arab world who value clarity over claims.
An FDA advisory committee recommended six peptides for compounding in July 2026 — but the objection from the agency's own scientists was about chemical identity, not efficacy. What the BPC-157 evidence actually consists of, why TB-500 is not thymosin beta-4, and the evidence graded by peptide and regulatory status.
A sleep or anti-stress drip is built on tryptophan, glycine and magnesium — but brain tryptophan entry tracks a ratio, not a dose, and the competitors travel in the same bag. What the two human infusion studies found, why glycine is the best-evidenced ingredient, and the evidence graded by ingredient and route.
No infusion delivers collagen — the molecule is a 300 kDa triple helix and the dermis builds its own, residue by residue. What a collagen drip actually contains, why the oral evidence disappears in the trials without industry funding, and the evidence graded by indication and route.
Oral biotin at supplement doses is about 100% bioavailable against an intravenous reference in the same subjects, so the drip closes no absorption gap. Three independent reviews found no benefit for hair growth in healthy adults, and the FDA has warned twice that biotin can hide a heart attack from the laboratory.
Levocarnitine injection is a licensed medicine with two deficiency indications — and its own label states that clinical outcomes in dialysis patients have not been determined. Why the saturated muscle transporter, not delivery, is the limiting step, with evidence graded by indication.
Magnesium sulfate halved eclampsia risk in a 10,141-woman trial and remains first-line for torsades de pointes — yet 64,000 randomised patients found no cardiac benefit after myocardial infarction, and the largest asthma trial missed its endpoint. Evidence graded by indication, with doses and safety limits.
Glutamine trials showed a mortality signal in critical illness, a 2024 trial showed amino acid infusion reduces kidney injury after cardiac surgery, and the 2023 taurine anti-aging finding was challenged twice in 2025. A molecule-by-molecule evidence review.
B12 and folate arrive in the IV clinic with better credentials than most infusion ingredients — and the manufacturer's own label advises against the intravenous route. What the methylation cycle does, what the outcome trials settled, and how to read a combined formulation.
Alpha-lipoic acid carries one of the most studied evidence bases of any IV antioxidant — four decades of named trials in diabetic neuropathy. An honest, evidence-graded look at what those trials show, and what the longevity marketing doesn't.
NAD+ IV therapy promises the fastest way to restore cellular energy. Here is what a 2024 head-to-head trial found when IV NAD+ was tested against its own precursor — and an honest look at the mechanism, dosing and safety.
High-dose IV vitamin C floods the bloodstream with concentrations no oral dose can reach. An honest, evidence-graded look at what it does in sepsis, oncology and deficiency — and the safety facts that matter.
Glutathione IV therapy delivers the body's master antioxidant directly into the bloodstream. Mechanism, evidence graded by indication, dosing protocols and the safety facts — for clinicians who need precision, not promises.
What's really in a Myers' cocktail, why it is given by IV, and an evidence-graded look at what it does and doesn't do — exact doses, the one RCT, and the safety facts.
NMN is a precursor; NAD+ is the coenzyme cells use. How the two differ in biochemistry, absorption and human evidence — an evidence-graded comparison for practice.